THERAPY DOSSIER · th-2014f8db25fa

Amniotic-fluid-derived mesenchymal stem cells transduced with lentiviral vector overexpressing human interleukin-1 receptor antagonist (IL-1Ra/MSCs)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 6

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT03233776 ↗PHASE2completed

Anakinra for Fever During Neutropenia and Mucositis After Autologous SCT in Multiple Myeloma

Multiple Myeloma

Enrolment: 9 · Results not recorded

NCT03578497 ↗PHASE2completed

Effects of Interleukin-1 Receptor Antagonism on Hyperandrogenemia in PCOS

Polycystic Ovary Syndrome

Enrolment: 18 · Results not recorded

NCT04072822 ↗PHASE2completed

Anakinra (Plus Zinc) or Prednisone in Patients With Severe Alcoholic Hepatitis

Alcoholic Hepatitis

Enrolment: 147 · Results not recorded

NCT03587701 ↗PHASE2recruiting

Anakinra in Corticosteroid-Resistant Meniere's Disease and Autoimmune Inner Ear Disease

Autoimmune Inner Ear Disease · Meniere's Disease

Enrolment: 57 · Results not recorded

NCT02390596 ↗PHASE2completed

Anakinra in IVIG-resistant Kawasaki Disease

Kawasaki Disease

Enrolment: 16 · Results not recorded

NCT03430011 ↗PHASE1/PHASE2completed

JCARH125 BCMA CAR-T With Anakinra in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

Enrolment: 165 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 22844472 ↗2012Reported benefit

Amniotic-fluid-derived mesenchymal stem cells overexpressing interleukin-1 receptor antagonist improve fulminant hepatic failure.

RatChemical/toxinSprague-Dawley (syngeneic S-D rats)Malen = 15 rats per group for the survival study (4 groups); n = 5…Portal vein transfusion via 28-gauge needle over 5 minutesCell dose reported as 1x10(n) MSCs in a volume of 0.8 mL; e…One day (24 h) after induction of fulminant hepatic failure

Model: Fulminant hepatic failure induced by intraperitoneal injection of D-galactosamine 1.5 g/kg plus lipopolysaccharide 200 ug/kg

21-day survival was 69.2% with IL-1Ra/MSCs and 63.6% with Lv/IL-1Ra versus 22.2% with physiological saline and 30.0% with GFP/MSCs (p < 0.05). IL-1Ra/MSC rats had lower serum ALT on day 5 (448.7 +/- 112.6 versus 657.3 +/- 147.4 IU/L) and day 7 (215.7 +/- 78.3 versus 435.8 +/- 122.7 IU/L), higher Br…

Extraction: extract · Supplied extraction confidence: 0.88. Machine-extracted fields require source verification.

Loading the evidence…